文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌高剂量率串联和卵圆形施源器近距离放疗:不良事件的剂量学预测因素

High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events.
PubMed 文献 · Radiat Oncol · 2018-07-16

该回顾性研究纳入56例FIGO IB1-IVA期宫颈癌患者,接受CT引导的高剂量率腔内近距离放疗,评估胃肠和泌尿生殖系统毒性。严重泌尿生殖不良事件(3级及以上)发生率为7.1%,严重胃肠不良事件为14.3%。作者建议膀胱累积D2cc剂量限值小于80 Gy,直肠和乙状结肠小于65 Gy。

要点

  • 56例局部晚期宫颈癌患者接受CT引导高剂量率腔内近距离放疗,任何泌尿生殖不良事件(1级及以上)发生率为23.3%,严重不良事件(3级及以上)为7.1%。
  • 任何胃肠不良事件发生率为26.8%,严重胃肠不良事件为14.3%。
  • 作者建议膀胱累积D2cc剂量限值小于80 Gy,直肠和乙状结肠小于65 Gy。

核心结论

  • 即使遵循当前美国近距离放疗学会指南,仍观察到严重不良事件,作者数据支持更严格的剂量学目标。
  • 作者建议累积D2cc剂量限值:膀胱小于80 Gy,直肠和乙状结肠小于65 Gy。

研究设计与样本

  • 回顾性评估接受CT引导高剂量率腔内近距离放疗的局部晚期宫颈癌患者队列。
  • 共纳入56例FIGO IB1-IVA期宫颈癌女性患者。
  • 使用线性二次模型计算累积剂量,根据CTCAE v4.0分级标准分析胃肠和泌尿生殖毒性的临床和剂量学预测因素。

主要发现

  • 任何泌尿生殖不良事件(1级及以上)总体发生率为23.3%(n=13),严重不良事件(3级及以上)为7.1%(n=4);4例严重事件中3例膀胱EQD2 D2cc≥80。
  • 任何胃肠不良事件总体发生率为26.8%(n=15),严重不良事件为14.3%(n=8);8例严重事件中6例直肠EQD2 D2cc≥65 Gy,7例乙状结肠D2cc≥65 Gy。
  • 在临床有意义的不良事件发展因素(糖尿病、吸烟状态、卵圆形施源器尺寸和治疗持续时间)中,未发现统计学显著的预后因素。

关键数值与推荐

  • 美国近距离放疗学会已发布高剂量率近距离放疗指南及推荐剂量限值,但近期报告提示可能需要更低剂量以避免毒性。
  • 作者建议累积D2cc剂量限值:膀胱小于80 Gy,直肠和乙状结肠小于65 Gy。

临床怎么用

  • 作者建议累积D2cc剂量限值:膀胱小于80 Gy,直肠和乙状结肠小于65 Gy。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. METHODS: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. RESULTS: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD2) D2cc was ≥80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD2 D2cc ≥ 65 Gy and seven patients had a sigmoid D2cc ≥ 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. CONCLUSIONS: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Romano KD, Hill C, Trifiletti DM, et al. High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events. Radiat Oncol. 2018. PMID: 30012164. doi:10.1186/s13014-018-1074-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。